Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5
Lynch Syndrome
National Cancer Institute (NCI)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Lynch Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid M.D. Anderson Cancer Center | Phase 3 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Acetylsalicylic Acid Lysinate Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Naproxen M.D. Anderson Cancer Center | Phase 2 | B |
Eloxatin National Cancer Institute (NCI) | Phase 3 | B |
View all 25 →
Same molecule, other indications
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →